Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04766476 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04766476 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 9 participants.
The verdict
NCT04766476, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.
Interventions
- DRUG BMS-963272
- OTHER Placebo matching BMS-963272
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2021-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04766476
The ClinicalTrials.gov registry entry for NCT04766476 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-963272 is the first listed.
NCT04766476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04766476 about?
NCT04766476 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease". The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.
What is the current status of trial NCT04766476?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-02-24. Estimated completion is 2021-08-12.
What interventions are being tested in trial NCT04766476?
The interventions under investigation include: BMS-963272 (DRUG), Placebo matching BMS-963272 (OTHER).
Who is sponsoring clinical trial NCT04766476?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.